Syndecan-4 is a transmembrane
heparan sulfate proteoglycan expressed in a variety of cells, and its
heparan sulfate glycosaminoglycan side chains bind to several
proteins exhibiting various biological roles. The authors have previously demonstrated syndecan-4's critical roles in
pulmonary inflammation. In the current study, however, its role in
pulmonary fibrosis was evaluated. Wild-type and syndecan-4-deficient mice were injected with
bleomycin, and several parameters of
inflammation and
fibrosis were analyzed. The
mRNA expression of
collagen and α-smooth muscle action (α-SMA) in lung tissues, as well as the histopathological lung
fibrosis score and
collagen content in lung tissues, were significantly higher in the syndecan-4-deficient mice. However, the total cell count and cell differentiation in bronchoalveolar lavage fluid were equivalent between the wild-type and syndecan-4-deficient mice. Although there was no difference in the TGF-β expression in lung tissues between the wild-type and syndecan-4-deficient mice, significantly more activation of Smad3 in lung tissues was observed in the syndecan-4-deficient mice compared to the wild-type mice. Furthermore, in the in vitro experiments using lung fibroblasts, the co-incubation of
syndecan-4 significantly inhibited TGF-β-induced Smad3 activation,
collagen and α-SMA upregulation. Moreover,
syndecan-4 knock-down by
siRNA increased TGF-β-induced Smad3 activation and upregulated
collagen and α-SMA expression. These findings showed that
syndecan-4 inhibits the development of
pulmonary fibrosis, at least in part, through attenuating TGF-β signaling.